Sleep Management And Recovery After Traumatic Brain Injury in Kids: Pilot Intervention of Melatonin (SMARTKids)
Primary Purpose
Traumatic Brain Injury, Critical Illness, Sleep
Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
melatonin
placebo
Sponsored by
About this trial
This is an interventional prevention trial for Traumatic Brain Injury focused on measuring pediatric, traumatic brain injury, melatonin, sleep, intervention
Eligibility Criteria
Inclusion:
- Children age ≥6 years and <19 years
- Traumatic brain injury defined as disruption of the normal function of the brain resulting from blunt force injury with a severity defined as mild complicated, moderate, or severe by the Glasgow Coma Scale with the presence of intracranial injury on imaging
- Admission to Oregon Health & Science University Hospitals
- Deemed likely to survive hospitalization by clinical care team
- Able to tolerate enteral medications within 72 hours of admission
- Child participant resides with parent or legal guardian
Exclusion:
- Lack stable means of communication with study team (phone, email, mailing address)
- Abusive trauma suspected or confirmed
- Dialysis
- Extracorporeal support (e.g. ECMO)
- Significant liver injury defined as >2x normal levels for AST or ALT
- Clinical team safety concerns with use of intervention
- Pregnancy
- Prisoners
Sites / Locations
- Oregon Health & Science UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Melatonin
Placebo
Arm Description
(melatonin doses of 3mg or 5mg based on patient size given nightly 1 hour prior to bedtime every night for 30 days)
Placebo
Outcomes
Primary Outcome Measures
sleep disturbance
Sleep Disturbances Scale for Children: 26-item parent proxy sleep questionnaire with higher scores reflecting greater disturbance and risk for clinically important sleep disorders. Each question is scored 1 through 5 for a range of possible total scores of 26 - 130.
Recruitment
Quantitative number of patients consented per patients approached
Retention
Quantitative number of participants completing trial procedures per patients consented
Secondary Outcome Measures
adherence quantitative
pill counts
adherence qualitative
participant report of compliance with treatment regimen evaluated by survey question estimating percentage of study days compliant with intervention
Fatigue
Pediatric Quality of Life Inventory Multidimensional Fatigue Scale (PedsQL MFS); 18 item parent proxy report of fatigue. Scores range 0-100 with higher scores indicating better function and less fatigue.
Chronotype
Children's Chronotype Questionnaire, parent reported survey of circadian rhythm characteristics. Each item assessed independently.
sleep latency
actigraphy measured time in minutes to fall asleep
total sleep time
actigraphy measured total time asleep in minutes
wake after sleep onset
actigraphy measured time in minutes awake after sleep onset
number of night awakenings
actigraphy measured number of instances awoken after sleep onset
sleep efficiency
actigraphy measure percentage of nighttime period spent asleep
sleep onset
time of day fell asleep
sleep offset
time of day waking from nighttime sleep
adverse events time 0
Evaluation of adverse events asking participants to report any side effects of study interventions
adverse events time 1
Evaluation of adverse events asking participants to report any side effects of study interventions
adverse events time 2
Evaluation of adverse events asking participants to report any side effects of study interventions
Full Information
NCT ID
NCT04932096
First Posted
June 2, 2021
Last Updated
January 5, 2023
Sponsor
Oregon Health and Science University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT04932096
Brief Title
Sleep Management And Recovery After Traumatic Brain Injury in Kids: Pilot Intervention of Melatonin
Acronym
SMARTKids
Official Title
Sleep Management And Recovery After Traumatic Brain Injury in Kids (SMARTKids): Evidence for Targeting Sleep to Improve Outcomes
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 2, 2023 (Actual)
Primary Completion Date
July 1, 2025 (Anticipated)
Study Completion Date
August 31, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Oregon Health and Science University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Sleep wake disturbances compound recovery in over half of pediatric traumatic brain injury survivors, leading to impaired quality of life, and few effective interventions exist to treat this important morbidity. Therefore, this study will conduct a randomized controlled trial evaluating a melatonin intervention started during hospitalization and continued after discharge compared to placebo. The trial will investigate if this intervention is feasible, acceptable, and effective at reducing sleep wake disturbances as measured on the Sleep Disturbances Scale for Children 1-month after hospital discharge.
Participants will be randomly assigned to receive the intervention (melatonin) or to the control group (placebo) with a goal of equal numbers of participants in each group and all will receive sleep education. Participants will be followed closely after consent and outcomes will be assessed at hospital discharge, 2-weeks, and 1-month. Outcomes will focus on feasibility (ability to recruit patients into the trial) and acceptability (patient safety and satisfaction), but will also assess the effectiveness of the intervention to reduce sleep disturbances after discharge. The investigators will assess sleep using questionnaires and actigraphy (watch-like activity monitors). Exploratory outcomes will include global health outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Traumatic Brain Injury, Critical Illness, Sleep
Keywords
pediatric, traumatic brain injury, melatonin, sleep, intervention
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
110 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Melatonin
Arm Type
Experimental
Arm Description
(melatonin doses of 3mg or 5mg based on patient size given nightly 1 hour prior to bedtime every night for 30 days)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
melatonin
Intervention Description
melatonin supplementation
Intervention Type
Other
Intervention Name(s)
placebo
Intervention Description
microcrystalline cellulose filled capsule
Primary Outcome Measure Information:
Title
sleep disturbance
Description
Sleep Disturbances Scale for Children: 26-item parent proxy sleep questionnaire with higher scores reflecting greater disturbance and risk for clinically important sleep disorders. Each question is scored 1 through 5 for a range of possible total scores of 26 - 130.
Time Frame
1-month
Title
Recruitment
Description
Quantitative number of patients consented per patients approached
Time Frame
through study completion, an average of 6-months
Title
Retention
Description
Quantitative number of participants completing trial procedures per patients consented
Time Frame
through study completion, an average of 6-months
Secondary Outcome Measure Information:
Title
adherence quantitative
Description
pill counts
Time Frame
1-month
Title
adherence qualitative
Description
participant report of compliance with treatment regimen evaluated by survey question estimating percentage of study days compliant with intervention
Time Frame
1-month
Title
Fatigue
Description
Pediatric Quality of Life Inventory Multidimensional Fatigue Scale (PedsQL MFS); 18 item parent proxy report of fatigue. Scores range 0-100 with higher scores indicating better function and less fatigue.
Time Frame
1-month
Title
Chronotype
Description
Children's Chronotype Questionnaire, parent reported survey of circadian rhythm characteristics. Each item assessed independently.
Time Frame
1-month
Title
sleep latency
Description
actigraphy measured time in minutes to fall asleep
Time Frame
1-month
Title
total sleep time
Description
actigraphy measured total time asleep in minutes
Time Frame
1-month
Title
wake after sleep onset
Description
actigraphy measured time in minutes awake after sleep onset
Time Frame
1-month
Title
number of night awakenings
Description
actigraphy measured number of instances awoken after sleep onset
Time Frame
1-month
Title
sleep efficiency
Description
actigraphy measure percentage of nighttime period spent asleep
Time Frame
1-month
Title
sleep onset
Description
time of day fell asleep
Time Frame
1-month
Title
sleep offset
Description
time of day waking from nighttime sleep
Time Frame
1-month
Title
adverse events time 0
Description
Evaluation of adverse events asking participants to report any side effects of study interventions
Time Frame
hospital discharge assessed up to 7 days
Title
adverse events time 1
Description
Evaluation of adverse events asking participants to report any side effects of study interventions
Time Frame
2 weeks
Title
adverse events time 2
Description
Evaluation of adverse events asking participants to report any side effects of study interventions
Time Frame
1-month
Other Pre-specified Outcome Measures:
Title
reason for non-adherence
Description
qualitative response to survey question about reasons for non-compliance with treatment regimen or sleep plan
Time Frame
1-month
Title
health related quality of life
Description
Pediatric Quality of Life Inventory (PedsQL): parent reported measure of quality of life. Scores range 0-100 with higher scores indicating better quality of life.
Time Frame
1-month
Title
cognitive functioning
Description
Behavior Rating Inventory of Executive Function, second edition (BRIEF-2); parent proxy report of everyday executive function, reported as standardized Global Executive Composite T-score, with higher scores indicating worse function. T-scores range from 0-100, with a mean of 50 and standard deviation of 10.
Time Frame
1-month
Title
physical functioning
Description
Functional Status Scale, range 6-30, with higher scores indicating worse function
Time Frame
1-month
Title
anxiety
Description
Patient Reported Outcome Measurement Information System (PROMIS) anxiety short form T-score with higher scores indicating worse outcome. T-scores range from 0 - 100, with a mean of 50 and standard deviation of 10.
Time Frame
1-month
Title
depression
Description
Patient Reported Outcome Measurement Information System (PROMIS) depression short form T-score with higher scores indicating worse outcome. T-scores range from 0-100, with a mean of 50 and standard deviation of 10.
Time Frame
1-month
Title
pain
Description
Patient Reported Outcome Measurement Information System (PROMIS) pain intensity (raw score out of 10), and pain behavior (T-score with mean of 50 and standard deviation of 10) parent report forms; Higher scores indicate worse pain outcomes
Time Frame
1-month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion:
Children age ≥6 years and <19 years
Traumatic brain injury defined as disruption of the normal function of the brain resulting from blunt force injury with a severity defined as mild complicated, moderate, or severe by the Glasgow Coma Scale with the presence of intracranial injury on imaging
Admission to Oregon Health & Science University Hospitals
Deemed likely to survive hospitalization by clinical care team
Able to tolerate enteral medications within 72 hours of admission
Child participant resides with parent or legal guardian
Exclusion:
Lack stable means of communication with study team (phone, email, mailing address)
Abusive trauma suspected or confirmed
Dialysis
Extracorporeal support (e.g. ECMO)
Significant liver injury defined as >2x normal levels for AST or ALT
Clinical team safety concerns with use of intervention
Pregnancy
Prisoners
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cydni N Williams, MD
Phone
503-494-5522
Email
willicyd@ohsu.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Andrea Rano, BS
Phone
503-494-5522
Email
rano@ohsu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cydni Williams, MD
Organizational Affiliation
Oregon Health and Science University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oregon Health & Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cydni Williams, MD
Phone
503-494-5522
Email
willicyd@ohsu.edu
First Name & Middle Initial & Last Name & Degree
Andrea Rano, BS
Phone
503-494-5522
Email
rano@ohsu.edu
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Basic tabular results will be entered into clinicaltrials.gov within 1 year of primary completion of the study. We will make participant data available to researchers once thoroughly de-identified and approved by our institutional review board within 1 year of study completion. Data will be made available on requests made directly to the Principal Investigator.
IPD Sharing Time Frame
The study protocol and SAP will be shared upon approval by the Institutional Review Board, and the final approved study protocol and SAP with documentation of any amendments will be available at study completion. The ICF will be shared no later than 60days from enrollment of the last study visit. A CSR and analytic code for the primary outcomes analysis will be made available within 1 year of study completion.
IPD Sharing Access Criteria
Requests for data can be made by contacting the Principal Investigator
Citations:
PubMed Identifier
32328648
Citation
Luther M, Poppert Cordts KM, Williams CN. Sleep disturbances after pediatric traumatic brain injury: a systematic review of prevalence, risk factors, and association with recovery. Sleep. 2020 Oct 13;43(10):zsaa083. doi: 10.1093/sleep/zsaa083.
Results Reference
background
PubMed Identifier
31797275
Citation
Poppert Cordts KM, Hall TA, Hartman ME, Luther M, Wagner A, Piantino J, Guilliams KP, Guerriero RM, Jara J, Williams CN. Sleep Measure Validation in a Pediatric Neurocritical Care Acquired Brain Injury Population. Neurocrit Care. 2020 Aug;33(1):196-206. doi: 10.1007/s12028-019-00883-5.
Results Reference
background
PubMed Identifier
31735567
Citation
Williams CN, Hartman ME, McEvoy CT, Hall TA, Lim MM, Shea SA, Luther M, Guilliams KP, Guerriero RM, Bosworth CC, Piantino JA. Sleep-Wake Disturbances After Acquired Brain Injury in Children Surviving Critical Care. Pediatr Neurol. 2020 Feb;103:43-51. doi: 10.1016/j.pediatrneurol.2019.08.010. Epub 2019 Aug 26.
Results Reference
background
Links:
URL
http://www.ohsu.edu/pccnrp
Description
Principal Investigator program website that will be updated regularly for PI contact information and study related materials
Learn more about this trial
Sleep Management And Recovery After Traumatic Brain Injury in Kids: Pilot Intervention of Melatonin
We'll reach out to this number within 24 hrs